The safety of treatment interruptions, a necessary part of cure studies, is not well-established, particularly in girls. We when results to men in historical disruption trials and explored security and viral rebound kinetics in a group of postpartum women quitting ART.
Test of time.
1,076 asymptomatic, virally suppressed, postpartum women living with HIV enrolled in the PROMISE trial with baseline CD4+ cell counts ≥ 350/mm3 underwent behavioral therapy (ART) discontinuation. Proportion with virologic suppression at weeks 4 and 12 were compared to participants in ACTG treatment interruption trials (91% male inhabitants ).
In PROMISE, with the median time to HIV viral rebound, methods was fourteen days. An estimated 6% of girls would stay suppressed at 30 weeks. Of those that had viral rebound by 30 months (N = 993),